The Lancet 柳叶刀· Mutsa Bwakura-Dangarembizi, Elizabeth Chappell, Cissy Kityo, Diana Louis Anena, Cecilia Kiilu, Moherndran Archary, Lungile Jafta, Hilda A Mujuru, Shamim Nakabuye, George P Akabwai, Abraham Siika, Rosie Mngqibisa, Henry Mugerwa, Simon Walker, Janet Seeley, David Burger, Anas Omar, Annabelle South, Hanh Nguyen, Carlo Giaquinto, Ben Spittle, Alasdair Bamford, Adeodata R Kekitiinwa, Deborah Ford, Sarah Pett, LATA trial team·· 2026-09-18精选AI 评分64
LATA 96周随机试验:每8周注射 cabotegravir–rilpivirine 维持青少年HIV病毒学抑制优于TLD
[Articles] Switch to injectable cabotegravir–rilpivirine given every 8 weeks in adolescents living with HIV with virological suppression in sub-Saharan Africa (LATA): a randomised, open-label, multicentre, 96-week non-inferiority trial
AI 导读
LATA 96周随机、开放标签、多中心非劣效试验显示,在病毒学抑制的撒哈拉以南非洲青少年HIV感染者中,每8周注射 cabotegravir–rilpivirine(LAI)维持病毒学抑制优于TLD方案,且未观察到新的安全性问题。研究团队认为,这些结果支持将 LAI cabotegravir–rilpivirine 作为该人群的维持治疗选择。
推荐理由
96周随机对照设计直接比较每8周注射方案与TLD,为青少年HIV维持治疗的给药方式选择提供对照证据。
来源:The Lancet 柳叶刀 · thelancet.com